Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Mirati Therapeutics, Inc. (MRTX)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 7.5% | 7.8% | 64.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Gross profit | 92.5% | 92.2% | 35.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 551.4% | 1025.4% | 7582.5% | | 1011.3% | 7609.4% | 14560.2% | |
| Research and development | 907.1% | 1767.6% | 15121.6% | 2413.5% | 2393.5% | 18473.3% | 51451.2% | 161.7% |
| General and administrative | | | -18091.8% | 1119.5% | | | -31151.8% | 49.0% |
| EBITDA | -1359.8% | -2689.4% | -22573.0% | -3419.8% | -3291.9% | -25894.1% | -65723.4% | -110.0% |
| Depreciation | 8.1% | 15.0% | 95.4% | 13.2% | 12.9% | 88.7% | 188.0% | 0.7% |
| EBIT | -1367.9% | -2704.4% | -22668.4% | -3432.9% | -3304.8% | -25982.8% | -65911.4% | -110.7% |
| Pre-tax income | -1292.3% | -2575.5% | -21651.1% | -3191.1% | -3290.7% | -26570.7% | -66762.5% | -106.9% |
| Income taxes | 0.0% | 0.0% | 27.2% | 4.7% | 0.0% | 0.0% | 0.0% | 4.6% |
| Net income | -1292.3% | -2575.5% | -21678.3% | -3195.7% | -3290.7% | -26570.7% | -66762.5% | -111.5% |
|